QR код

Uneven Implementation of Nirsevimab Prophylaxis Resulted in Non-Uniform Reductions in RSV-Related Hospitalizations in Italy

Background/Objectives: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants. In the 2024–2025 season, passive newborn immunization with nirsevimab, a long-acting anti-RSV monoclonal antibody, was introduced for the first time in Italy. However, the im...

Повний опис

Збережено в:
Автори: Melodie O. Aricò, Francesco Accomando, Daniela Trotta, Giulia Marozzi, Anthea Mariani, Claudia Rossini, Claudio Cafagno, Letizia Lorusso, Martina Fornaro, Enrico Valletta, Désirée Caselli, Maurizio Aricò
Формат: Artigo
Мова:Inglês
Опубліковано: MDPI AG 2025-09-01
Серія:Infectious Disease Reports
Предмети:
bronchiolitis
respiratory syncytial virus
nirsevimab
health disparities
Онлайн доступ:https://www.mdpi.com/2036-7449/17/5/115
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси